4.7 Article

Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs

期刊

CLINICAL CHEMISTRY
卷 68, 期 7, 页码 953-962

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/clinchem/hvac032

关键词

cancer; molecular diagnostics; epidemiology studies

资金

  1. National Key R&D Program of China [2020YFC1316905]
  2. National Natural Science Foundation of China [81872700, 82073625]
  3. Planned Science and Technology Project of Guangdong Province [2019B020230002]
  4. Heath&Medical Collaborate Innovation Project of Guangzhou City, China [201803040003]
  5. Sun Yat-Sen University Clinical Research 5010 Program [2013012]
  6. Intramural Research Program of National Cancer Institute (NCI), USA

向作者/读者索取更多资源

This study evaluated the performance of nasopharynx swab EBV DNA as a reflex test to triage high-risk individuals for nasopharyngeal carcinoma (NPC). The results showed that the swab test had promising potential in reducing referral rate without significantly compromising sensitivity compared to serology-only screening programs.
Background Epstein-Barr virus (EBV) DNA detection in the nasopharynx is considered a biomarker for nasopharyngeal carcinoma (NPC). We evaluated its performance as a reflex test to triage EBV seropositives within an NPC screening program in China. Methods The study population was embedded within an ongoing NPC screening trial and included 1111 participants who screened positive for anti-EBV VCA (antibodies against EBV capsid antigens)/EBNA1 (EBV nuclear antigen1)-IgA antibodies (of 18 237 screened). Nasopharynx swabs were collected/tested for EBNA1 gene EBV DNA load. We evaluated performance of EBV DNA in the nasopharynx swab as a reflex test to triage EBV serological high-risk (those referred to endoscopy/MRI) and medium-risk (those referred to accelerated screening) individuals. Results By the end of 2019, we detected 20 NPC cases from 317 serological high-risk individuals and 4 NPC cases from 794 medium-risk individuals. When used to triage serological high-risk individuals, nasopharynx swab EBV DNA was detected in 19/20 cases (positivity rate among cases: 95.0%; 95% CI, 75.1%-99.9%), with a referral rate of 63.4% (201/317, 95% CI, 57.8%-68.7%) and NPC detection rate among positives of 9.5% (19/201, 95% CI, 5.8%-14.4%). The performance of an algorithm that combined serology with triage of serology high-risk individuals using EBV DNA testing yielded a sensitivity of 72.4% (95% CI, 3.0%-81.4%) and specificity of 97.6% (95% CI, 97.2%-97.9%). When used to triage EBV serological medium-risk individuals, the positivity rate among cases was 75.0% (95% CI, 19.4%-99.4%), with a referral rate of 61.8% (95% CI, 58.4%-65.2%) and NPC detection rate among positives of 0.6% (95% CI, 0.1%-1.8%). Conclusions Nasopharynx swab EBV DNA showed promise as a reflex test to triage serology high-risk individuals, reducing referral by ca. 40% with little reduction in sensitivity compared to a serology-only screening program.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据